Latest news and articles about Jumpcan Bio
Total: 1 articles found
The global iPSC therapy market has entered a critical clinical phase following Japan's landmark 2026 conditional approvals for heart failure and Parkinson's treatments. While breakthroughs in China and the US demonstrate the curative potential for chronic diseases, the industry must now solve the dual challenges of high manufacturing costs and regulatory safety monitoring.
